+5.1%
DHR vs GSK
+31.2%
-26.1%
-33.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.6% | -1.9% | +0.3% | -1.0% |
| 7D | -3.9% | -1.8% | -2.1% | -3.3% |
| 30D | +4.0% | -2.2% | +6.2% | +4.7% |
| 3M | +11.5% | -1.8% | +13.3% | +11.9% |
| 6M | +1.9% | -10.6% | +12.5% | +5.5% |
| YTD | -8.9% | +4.4% | -13.3% | -12.5% |
| 1Y | +5.1% | +30.4% | -25.3% | -14.0% |
| All | +5.1% | +31.2% | -26.1% | -14.0% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling